---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014482"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:50:35.769264+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q2 net loss $7.7M; Phase 1 trial submission for GT-02287

## Summary
- Net loss $7.7M ($0.62/share) vs $5.1M ($0.43) in Q2 2022, driven by higher R&D and G&A costs.
- R&D expenses $4.0M, up $1.4M YoY due to preclinical studies and manufacturing for GBA1 Parkinson's program.
- Cash and securities $16.2M; company expects to fund operations into Q3 2024.
- Submitted HREC dossier to initiate Phase 1 trial of GT-02287 in Australia in H2 2023.
- Late-breaking abstract accepted for presentation at International Congress of Parkinson's Disease.

## SEC filing metadata
- accession: 0001558370-23-014482
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837023014482/0001558370-23-014482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837023014482/ganx-20230810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014482
- JSON: https://secwatch.observer/filing/0001558370-23-014482.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014482.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $7.7 million, or $0.62 per share basic and diluted, EPS $0.62 per share basic and diluted.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023, was $7.7 million, or $0.62 per share basic and diluted
  - EPS: $0.62 per share basic and diluted
  - Result: reported results
  source text: Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837023014482/0001558370-23-014482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.